Trial evaluates purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

FHS
July 31, 2023
2:48 pm

Researchers investigated the safety and pharmacokinetics of JNJ-54175446 in a double-blind, multicenter, randomized controlled trial (RCT).

Opinion | Charting the Course: From Young Adult Leukemia Patient to Oncologist

Rosenthal is a lymphoma specialist. “Would you like to have a bone marrow biopsy today or tomorrow?” These are the only words I remember coming

December 4, 2023

Novel Therapy Promising for Radiation-Induced Oral Mucositis

The first-in-class uridine phosphorylase inhibitor TK-90 almost completely eliminated severe oral mucositis (SOM) in patients with non-metastatic squamous cell carcinoma of the head and neck

March 5, 2024

Roasted green tea boosts mental task performance, study finds

Study examines how the consumption of green tea and roasted green tea affects human responses during mental tasks, demonstrating that roasted green tea can enhance

April 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.